Evidence map›Paper›PMID 38757057›Full record

ArticleMaterials today. Bio2024

A personalized osteoarthritic joint-on-a-chip as a screening platform for biological treatments.

Dalila Petta, Daniele D'Arrigo, Shima Salehi, Giuseppe Talò, Lorenzo Bonetti, Marco Vanoni, Luca Deabate, Luigi De Nardo, Gabriele Dubini, Christian Candrian and 3 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dalila PettaRegenerative Medicine Technologies Lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa, 5, 6500, Bellinzona, Switzerland.
Daniele D'ArrigoRegenerative Medicine Technologies Lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa, 5, 6500, Bellinzona, Switzerland.
Shima SalehiCell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via Belgioioso 173, 20157, Milan, Italy.
Giuseppe TalòCell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via Belgioioso 173, 20157, Milan, Italy.
Lorenzo BonettiDepartment of Chemistry, Materials and Chemical Engineering G.Natta, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milan, Italy.
Marco VanoniISBE-SYSBIO Centre of Systems Biology, Milan, Italy at Department of Biotechnology and Biosciences, Università Degli Studi di Milano Bicocca, Piazza Della Scienza 2, 20126, Milan, Italy.
Luca DeabateService of Orthopaedics and Traumatology, Department of Surgery, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland.
Luigi De NardoDepartment of Chemistry, Materials and Chemical Engineering G.Natta, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milan, Italy.
Gabriele DubiniDepartment of Chemistry, Materials and Chemical Engineering G.Natta, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milan, Italy.
Christian CandrianService of Orthopaedics and Traumatology, Department of Surgery, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland.
Matteo MorettiRegenerative Medicine Technologies Lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa, 5, 6500, Bellinzona, Switzerland.
Silvia LopaCell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via Belgioioso 173, 20157, Milan, Italy.
Chiara ArrigoniRegenerative Medicine Technologies Lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa, 5, 6500, Bellinzona, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a highly disabling pathology, characterized by synovial inflammation and cartilage degeneration. Orthobiologics have shown promising results in OA treatment thanks to their ability to influence articular cells and modulate the inflammatory OA environment. Considering their complex mechanism of action, the development of reliable and relevant joint models appears as crucial to select the best orthobiologics for each patient. The aim of this study was to establish a microfluidic OA model to test therapies in a personalized human setting. The joint-on-a-chip model included cartilage and synovial compartments, containing hydrogel-embedded chondrocytes and synovial fibroblasts, separated by a channel for synovial fluid. For the cartilage compartment, a Hyaluronic Acid-based matrix was selected to preserve chondrocyte phenotype. Adding OA synovial fluid induced the production of inflammatory cytokines and degradative enzymes, generating an OA microenvironment. Personalized models were generated using patient-matched cells and synovial fluid to test the efficacy of mesenchymal stem cells on OA signatures. The patient-specific models allowed monitoring changes induced by cell injection, highlighting different individual responses to the treatment. Altogether, these results support the use of this joint-on-a-chip model as a prognostic tool to screen the patient-specific efficacy of orthobiologics.

Indexed as

CartilageChondrogenic matrixInflammationJoint-on-a-chipMesenchymal stem cellsMicrofluidicsOrthobiologicsOsteoarthritis

Identifiers

PMID38757057
PMCPMC11097088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.